No abstract available
MeSH terms
-
Antibodies, Monoclonal / adverse effects*
-
Antibodies, Monoclonal, Humanized / adverse effects*
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
-
Dexamethasone / administration & dosage
-
Drug Approval
-
Drug Labeling*
-
Humans
-
Immunologic Factors / adverse effects
-
Immunotherapy / adverse effects*
-
Kaplan-Meier Estimate
-
Multiple Myeloma / drug therapy*
-
Multiple Myeloma / mortality
-
Nivolumab
-
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
-
Thalidomide / analogs & derivatives
-
United States
-
United States Food and Drug Administration
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Immunologic Factors
-
Programmed Cell Death 1 Receptor
-
Nivolumab
-
Thalidomide
-
Dexamethasone
-
pembrolizumab